References

1. Check W. Clues pile up, suggesting broad BNP role. CAP Today, 2004; 18(4): 1,64,66,68,70,72.

2. Christenson RH, Apple, FS, Cannon CP, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Biomarkers of acute coronary syndrome and heart failure. Available at: http://www.nacb.org/lmpg/card_biomarkers_lmpg_draft.stm Accessed May 7, 2004.

3. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides. A review. Clin Chem. 2004; 50(1): 33-50.

4. Yeo K-T J, Wu AHB, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003; 338: 107-115.

5. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994; 90: 195-203.

6. Yoshimura M, Yasue H, Okumura K, et al. Cardiac failure: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993; 87: 464-469.

7. Omland T, Asbjorn A, Vik-Mo H, et al. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart. 1996; 76: 232-237.

8. McDonagh T, Robb S, Murdoch D, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998; 351: 9-13.

9. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. J Am Coll Cardiol. 2001; 37: 379-385.

10. Maisel A, Krishnaswamy P, Nowak R, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161-167.

11. Morrison L, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002; 39: 202-209.

12. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure. J Am Coll Cardiol. 2001; 38(7): 2101-2113.

13. Allen P. Congestive heart failure and beyond. Clin Lab News. 2003; 29(7): 1,6,8.

14. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001; 22: 1527-1560.

15. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355: 1126-1130.

16. Shimizu et al. Clin Chim Acta. 2001; 305: 181-186.

17. Crockett H. BNP: A convenient and cost-effective rule-out tool for heart failure. Clin Lab Int. 2004; 28: 18-19.

18. Neilsen OW, et al. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol. 2003; 41(1): 113-120.

19. Developing services for heart failure. (Published by the U.K. Department of Health, 2003). Available at: http://www.doh.gov.uk
Accessed May 14, 2004.

20. Mueller C, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dsypnea. N Engl J Med. 2004; 350(7): 647-654.